SYC-435

SYC-435 is a small molecule inhibitor specifically targeting mutant isocitrate dehydrogenase 1 (IDH1). Developed by researchers at Vanderbilt University and Baylor College of Medicine, it is a 1-hydroxypyridin-2-one derivative designed to block the production of the oncometabolite D-2-hydroxyglutarate (D-2HG) from α-ketoglutarate. In preclinical studies, SYC-435 has demonstrated high selectivity for mutant IDH1 (e.g., R132H, R132C) over the wild-type enzyme. It has shown synergistic effects when combined with standard therapies like temozolomide and radiation in patient-derived orthotopic xenograft models of IDH1-mutant glioma, significantly prolonging survival.

Other names

1-hydroxypyridin-2-one